Four cases of ticlopidine-induced cholestatic hepatitis / 대한내과학회지
Korean Journal of Medicine
;
: 557-561, 2002.
Article
in Korean
| WPRIM
| ID: wpr-169315
ABSTRACT
Ticlopidine, a potent antiplatelet agent, is widely used for treatment of coronary artery disease and cerebrovascular disease. Adverse effects has been reported in 10% to 20% of patients receiving ticlopidine. The most commom adverse effects were gastrointestinal disturbance, skin rash, but cholestatic hepatitis with jaundice was rare (0.1% incidence). We have recently experienced four cases of ticlopidine-induced cholestatic hepatitis after coronary artery stent insertion. Jaundice developed within 1 month of starting ticlopidine at recommended daily doses. In all cases, jaundice resolved and serum liver enzymes improved over a period of months after drug withdrawal. Therefore, clinicians should be aware of the reversible condition of ticlopidine-induced cholestatic jaundice that slowly resolves after drug withdrawal.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Coronary Artery Disease
/
Ticlopidine
/
Stents
/
Coronary Vessels
/
Jaundice, Obstructive
/
Exanthema
/
Hepatitis
/
Jaundice
/
Liver
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2002
Type:
Article
Similar
MEDLINE
...
LILACS
LIS